{"id":"W2900694112","doi":"10.1182/blood-2018-99-111370","title":"Ibrutinib + Obinutuzumab Versus Chlorambucil + Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results from Phase 3 iLLUMINATE","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Chronic lymphocytic leukemia; Medicine; Leukemia; Lymphoma; Internal medicine; Immunology; Oncology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0004877551,0.001446792,0.001857985,0.0006983334,0.000454756,0.0001937338,0.0009058167,0.0007159953,0.0007287654],"category_scores_gemma":[0.001175917,0.001086326,0.0003704342,0.001760873,0.001122276,0.0003609372,0.0004337639,0.0003341444,0.001714562],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.5086357,"about_ca_system_score_gemma":0.1987443,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04996858,"about_ca_topic_score_gemma":0.01561234,"domain_scores_codex":[0.9913085,0.0002251019,0.001657209,0.002504876,0.001818106,0.002486212],"domain_scores_gemma":[0.9934055,0.001147067,0.0006073911,0.002982752,0.0007061156,0.001151196],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8227845,0.0140512,0.001287019,0.001469521,0.007981084,0.0231413,0.01151536,0.003226563,0.0008119124,0.0001196957,0.001977372,0.1116344],"study_design_scores_gemma":[0.8753395,0.04325472,0.002097547,0.001527571,0.001599725,0.0004226217,0.0002566242,0.03824548,0.02067786,0.00002843552,0.01511586,0.001434034],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910008,0.0006458098,0.00001229853,0.00009326835,0.0007460215,0.003472323,0.0006863021,0.0004402138,0.002902949],"genre_scores_gemma":[0.9908353,0.0005935496,0.0006107183,0.0001916053,0.001436268,0.0004358528,0.001742391,0.0003187864,0.003835499],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3098914,"threshold_uncertainty_score":0.9998282,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03171698714767747,"score_gpt":0.2927602090941959,"score_spread":0.2610432219465184,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}